Related Experiment Video
Updated: May 16, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
[Metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes]
H Gutiérrez-Hermosillo1, E Díaz de León-González, D Beltrán Santiago
1Departamento de Medicina Interna, Unidad Médica de Alta Especialidad n.o 25, Instituto Mexicano del Seguro Social, IMSS, Monterrey, México. hugocus@hotmail.com
Unlabelled:
Diabetes mellitus is a pathology that has widely spread througout the world in the past decades. Postprandial hyperglycemia plays an important role in the progress of the disease due to the fact that increases the risk for cardiovascular events. This study's aim was to determine if the use of intravenous metoclopramide in patients with Diabetes Mellitus increases the postprandial glycemia.
Material And Methods:
A cohort of patients hospitalized with type 2 diabetes mellitus. Patients were classified as exposed (metoclopramide 10 mg IV) and not exposed, and glycemia preprandial and postprandial at 30, 60 and 120 minutes was measured.
Results:
There were 80 patients in each group, and in both groups the general characteristics were homogeneous. The postprandial glycemia in the exposed group was higher at 30, 60, 90 and 120 minutes, being only statistically significant at 120 minutes postprandial (p = < 0,001).
Conclusions:
In conclusion, the use of intravenous metoclopramide is a risk factor to develop postprandial hyperglycemia in diabetic patients.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hyperglycemia
Diabetes Mellitus: Type 2 and Gestational
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
